Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks

Trial Profile

Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2015

At a glance

  • Drugs Beloranib (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Zafgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 May 2015 According to Zafgen media release, results presented at the 22nd European Congress on Obesity (ECO).
    • 08 May 2015 Results published in the Zafgen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top